Shockwave™Peripheral Intravascular Lithotripsy Balloon for Advanced Endovascular Aortic Repair
Launched by REDE OPTIMUS HOSPITALAR SA · Mar 20, 2024
Trial Information
Current as of July 04, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial, called Shockwave TEVAR, is looking at a new treatment method for patients with certain types of aortic aneurysms, which are bulges in the aorta that can be dangerous if not treated. The study specifically focuses on using the Shockwave™ Peripheral Intravascular Lithotripsy Balloon to help improve access to blood vessels when performing a procedure called TEVAR (Thoracic Endovascular Aortic Repair). This is important when the blood vessels leading to the aorta are difficult to work with due to heavy calcification or narrowing.
To participate in the trial, you must be at least 18 years old and have a specific type of aortic aneurysm that requires a special type of graft. You also need to have challenging access in your iliac arteries, which are the large blood vessels in your pelvis. The trial is open to both men and women and will involve a procedure where the Shockwave device is used before inserting the main graft. Participants will be closely monitored to see how well this new approach works. It’s important to know that patients who have had certain previous surgeries or specific conditions may not be eligible for this study.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Patient (m/f) age ≥ 18 years at time of enrollment.
- • 2. Diagnosis of thoracic and/or thoraco-abdominal (Extent I-V) and juxta/para-renal/short-neck aneurysm requiring the implantation of a thoracic and/or thoraco-abdominal fenestrated/branched aortic endograft with delivery system introducer sheath diameter equal or larger than 18 Fr (6 mm).
- 3. Hostile iliac access was defined in the presence of:
- • Heavily circumferential calcified iliac arteries
- • Inner diameter ≤ 6 mm
- • Severe stenosis (\> 50%; \> 2.5 m/s peak velocity; absence of triphasic duplex signal in ipsilateral common femoral artery)
- 4. We will accept the following presentations of aneurysm:
- • urgent cases,
- • elective,
- • symptomatic
- • and fast growing.
- • 5. The repair was performed using Shockwave™ before the introduction of the main endograft. The iliac procedures can be accompanied by angioplasty and/or stent and stent-graft positioning.
- Exclusion Criteria:
- • 1. Patients submitted to surgical conduit bypass.
- • 2. Not-severely calcified disease (absence of calcification).
- • 3. In-stent restenosis/occlusion.
- • 4. Inability to cross with 0.014 guidewire.
- • 5. Any significant medical condition which, in the investigator's opinion, may interfere with the subject's optimal participation in the study.
- • 6. Pre-stented iliac access vessels at the level of Shockwave implementation.
About Rede Optimus Hospitalar Sa
Rede Optimus Hospitalar SA is a leading healthcare organization committed to advancing medical research and improving patient outcomes through innovative clinical trials. With a focus on excellence in patient care and a robust infrastructure, the organization collaborates with healthcare professionals and research institutions to facilitate the development of cutting-edge therapies. By prioritizing ethical standards and regulatory compliance, Rede Optimus Hospitalar SA aims to contribute significantly to the medical community and enhance the quality of life for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Verona, Veneto, Italy
Münich, Bavaria, Germany
Nürnberg, Bavaria, Germany
Genova, Liguria, Italy
Bern, Canton Bern, Switzerland
Patients applied
Trial Officials
Marc Bosiers, Dr.
Study Director
Rede Optimus Hospitalar AG
Nikolaos Tsilimparis, Prof.
Principal Investigator
Department of Vascular Surgery, LMU Hospital Munich
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported